DZS Clinical Services, a Bound Brook, N.J.-based global provider of clinical development and data analytic services, has selected George Harb, M.D., as its new vice president of clinical and medical affairs.
The addition of Harb to the leadership team will augment DZS’ clinical development management and protocol design capabilities, as well as aid the company’s expansion into the Middle East and North Africa (MENA) region.
Harb has more than 16 years of experience in global drug development and medical affairs involving biologics and small molecule drugs. Prior to joining DZS, he served as vice president of clinical development and operations at Aptalis Pharma.
“Dr. Harb has an essential role in our growth as a global clinical services solutions provider,” said Greg Ambra, vice president of clinical operations at DZS. “His industry experience will significantly benefit our clients and also allow us to expand services in the emerging MENA region market.”
DZS partnered with SBI Pharmaceuticals as it completed one of the first industry-sponsored clinical studies in Bahrain. DZS provided project management, statistical and data management as well as local monitoring support in a study of the safety and efficacy of 5-aminolevulinic acid in the treatment of patients with Type II diabetes.
“DZS was instrumental in the completion of this study,” said Riyadh Rehani, Ph.D., MENA region president for SBI Pharmaceuticals. “This is a significant achievement in advancing clinical research in Bahrain, and we look forward to partnering with DZS to bring more clinical trials to the region.”
DZS provides clinical development and data analytic services for global pharmaceutical, biotech and medical device companies. The company delivers improved clinical trial performance through clinical project and data management, clinical monitoring, medical writing, staffing and recruitment. It leverages its proprietary eClinical software platform ClinPlus to help clinical study teams manage the collection of clinical data.